Tirzepatide vs Ozempic—A Comparison
Both tirzepatide (Mounjaro) and Ozempic (semaglutide) are GLP-1 receptor agonists, but tirzepatide also targets GIP receptors, offering a dual-action benefit.
Key Differences in Results
- Weight Loss: Clinical studies show tirzepatide may lead to greater weight loss than Ozempic.
- Blood Sugar Control: Both are effective, but tirzepatide shows slightly better A1C reduction.
- Side Effects: Similar profiles—nausea, vomiting, and gastrointestinal issues.
In conclusion, while both drugs are effective, tirzepatide’s dual-hormone mechanism may offer a slight edge for weight loss. That said, Ozempic remains a trusted and widely available choice.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or adjusting any medication.
